Principal Securities, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Principal Securities, Inc.
- $4.14 Trillion
- Q3 2024
A detailed history of Principal Securities, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 763 shares of APLS stock, worth $25,339. This represents 0.0% of its overall portfolio holdings.
Number of Shares
763
Previous 591
29.1%
Holding current value
$25,339
Previous $22.7 Million
2.94%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding APLS
# of Institutions
308Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$517 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$395 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$369 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$326 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$192 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.65B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...